AstraZeneca Joins the In-Licensing Game
Executive Summary
Much of AstraZeneca's newly-in-licensed bounty is high-risk. But it provides a low-cost pipeline boost, and marks a sharp turnaround at the firm.
You may also be interested in...
BMS Deals Diabetes Drugs, Solidifies Specialist Stance
The recent diabetes alliance between Bristol-Myers Squibb and AstraZeneca on two late-stage clinical compounds highlights some of the different ways pharmaceutical companies are embracing both specialty products and externalization strategies to address the industry's growing pipeline problem. BMS and AZ are pursuing different approaches but in diabetes, those strategies are complementary: AZ's unabashed externalization and muscular primary care marketing suits BMS's gradual weaning off the blockbuster model.
BMS Deals Diabetes Drugs, Solidifies Specialist Stance
The recent diabetes alliance between Bristol-Myers Squibb and AstraZeneca on two late-stage clinical compounds highlights some of the different ways pharmaceutical companies are embracing both specialty products and externalization strategies to address the industry's growing pipeline problem. BMS and AZ are pursuing different approaches but in diabetes, those strategies are complementary: AZ's unabashed externalization and muscular primary care marketing suits BMS's gradual weaning off the blockbuster model.
Genentech and Inotek Pair Up in PARP Inhibition
For the first time, oncology drug development is being grounded in the ability to take advantage of a readily identifiable genetic flaw in certain types of tumor cells. Research reveals that tumor cells containing the BRCA1 or BRCA2 gene variants are exquisitely sensitive to attack by inhibitors of poly (ADP-ribose) polymerase, or PARP. Now comes a deal between PARP specialist Inotek Pharmaceuticals and Genentech.